Procaryotic Micro-organism Patents (Class 435/71.2)
-
Publication number: 20080044860Abstract: Macrolides particularly erythromycins and azithromycins, having O-mycaminosyl or O-angolosaminyl groups, particularly at the 5-position, are produced using a gene cassette comprising a combination of genes which, in an appropriate strain background, are able to direct the synthesis of mycaminose or angolosamine and to direct its subsequent transfer to an aglycone or pseudoaglycone. Synthetic genes may comprise one or more of angMIII, angMI, angB, angAI, angAII, angorf14, angorf4, tylMIII, tylMI, tylB, tylAI, tylAII, eryCVI, spnO, eryBVI, eryK, tyl Ia and ery G. Glycosyltransfer genes may comprise one or more of eryCIII, tylMII, angMII, desVII, eryBV, spnP and midI.Type: ApplicationFiled: November 29, 2004Publication date: February 21, 2008Inventors: Sabine Gaisser, Stephen Frederick Haydock, Peter Francis Leadlay, Hamish Alastair Irvine Mcarthur
-
Publication number: 20080038778Abstract: A method for breeding yeast having thermotolerance or recovering growth activity and a method for breeding yeast which produces beta-glucan efficiently as well as an yeast obtained by such methods for breeding are presented by a method for breeding yeast having thermotolerance or recovering growth activity including a step for controlling proofreading function of DNA polymerase in a loss-of-function mutant of yeast (for example, a step for including mutant pol3 gene or mutant cdc6?gene in a gene-disruptant.Type: ApplicationFiled: March 2, 2007Publication date: February 14, 2008Applicants: National Institute of Advanced Industrial Science and Technology, Neo-Morgan Laboratory IncorporatedInventors: Hiroko Abe, Kenichi Nakayama, Yoshifumi Jigami, Yasunori Chiba, Yuki Takaoka, Akiko Itadani
-
Patent number: 7329513Abstract: The present invention relates to a process for preparing anthrax protective antigen protein from E. coli using fed batch culture. This process creates a constitutively expressing system for rapid, efficient, cost-effective and high-level production of anthrax PA from E. coli. The steps of the process involves, transforming E. coli DH5? cells with the recombinant constitutive expression plasmid containing the PA gene to obtain recombinant DH5? cells and testing the PA expression by lysis of said cells followed by denaturing gel electrophoresis and Western Blotting technique using PA antibodies. This is followed by fermentation and harvesting of the high cell density cells. The said cells are solubilized using 6-8 Molar Urea and separated by centrifugation. The urea denatured PA is isolated from said supernatant and purified and thereafter eluted.Type: GrantFiled: December 7, 2001Date of Patent: February 12, 2008Inventors: Rakesh Bhatnagar, Waheed Sayed Mohsin, Vibha Chauhan
-
Patent number: 7326545Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a 98 kDa outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa outer membrane protein gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: December 20, 2002Date of Patent: February 5, 2008Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 7300790Abstract: The present invention relates to non-vaccinal and non-pharmacologic compositions and methods for controlling complex retroviral infections. In particular, the present invention provides transgenic animals expressing a transdominant negative Rex gene product that inhibits retroviral replication.Type: GrantFiled: January 23, 2004Date of Patent: November 27, 2007Assignee: ioGenetics, LLCInventors: Kurt Eakle, Thomas Hope, Eun-A Choi, Jane Homan, Robert D. Bremel
-
Patent number: 7297514Abstract: A method of reducing superoxide damage to a cell is disclosed. In one embodiment, this method comprises the step of engineering the cell to produce more than a native amount of the YggX protein or its homolog, wherein the cells are rendered more resistant to superoxide damage.Type: GrantFiled: September 18, 2001Date of Patent: November 20, 2007Assignee: Wisconsin Alumni Research FoundationInventors: Diana Downs, Jeff A. Gralnick
-
Patent number: 7297341Abstract: The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100686 RY 54 (SEQ ID Nos: 1 and 14), CPN100696 RY-55 (SEQ ID Nos: 2 and 15), CPN100709 RY-57 (SEQ ID Nos: 3 and 16), CPN100710 RY-58 (SEQ ID Nos: 4 and 17), CPN100711 RY-59 (SEQ ID Nos: 5 and 18), CPN100877 RY-61 (SEQ ID Nos: 6 and 19), CPN100325 RY-62 (SEQ ID Nos: 7 and 20), CPN100368 RY-63 (SEQ ID Nos: 8 and 21), CPN100624 RY-64 (SEQ ID Nos:9 and 22), CPN100633 RY-65 (SEQ ID Nos:10 and 23), CPN100985 RY-66 (SEQ ID Nos:11 and 24), CPN100987 RY-67 (SEQ ID Nos:12 and 25) and CPN100988 RY-68 (SEQ ID Nos:13 and 26).Type: GrantFiled: December 23, 1999Date of Patent: November 20, 2007Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang
-
Patent number: 7282354Abstract: There is provided a fermented milk product that contains lactic acid bacteria capable of producing a large amount of lactotripeptide and a large amount of active ingredient having hypotensive activity and anti-stress effect, and that can be taken pleasantly as foods or beverages. Lactic acid bacteria of Lactobacillus helveticus having specific bacteriological properties, the bacteria, when cultured in a medium of animal milk containing 9 wt % solid of non-fat milk, producing tripeptides Val-Pro-Pro and Ile-Pro-Pro in an amount of 60 ?g in terms of Val-Pro-Pro per ml medium, and the bacteria exhibiting extracellular proteinase activity of not lower than 400 U/OD590. Lactobacillus helveticus CM4 strain (deposited at National Institute of Bioscience and Human-Technology Agency of Industrial Science and Technology, deposition number FERM BP-6060). A fermented milk product obtained by fermenting an animal milk with these lactic acid bacteria.Type: GrantFiled: December 5, 2002Date of Patent: October 16, 2007Assignee: Calpis Co., Ltd.Inventors: Naoyuki Yamamoto, Natsue Kawakami, Yuu Ishida, Hirokazu Yada
-
Patent number: 7264949Abstract: The promoter region associated with the Yarrowia lipolytica glycerol-3-phosphate O-acyltransferase (gpat) gene has been found to be particularly effective for the expression of heterologous genes in oleaginous yeast. The promoter regions of the instant invention have been shown to be suitable to drive high-level expression of genes involved in the production of ?-3 and ?-6 fatty acids.Type: GrantFiled: September 13, 2005Date of Patent: September 4, 2007Assignee: E.I. du Pont de Nemours and CompanyInventors: Zhixiong Xue, Quinn Qun Zhu
-
Patent number: 7258996Abstract: The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent of casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of an active agent, in which a food grade bacteria of the genus Lactobacillus helveticus is contacted with casein in order to perform a hydrolysis and obtain casein-derived peptides exhibiting metalloproteinases inhibitory property. The present invention also includes isolated and purified inhibitory peptides obtained by hydrolysis of casein by the bacteria.Type: GrantFiled: October 28, 2004Date of Patent: August 21, 2007Assignee: Nestec S.A.Inventors: Marcel-Alexandre Juillerat, Marie-Claude Robert
-
Patent number: 7256018Abstract: Provided are a microorganism capable of producing L-threonine and having an inactivated tyrR gene, a method of producing the same and a method of producing L-threonine using the microorganism. The microorganism can be used to produce L-threonine in high yield.Type: GrantFiled: February 4, 2005Date of Patent: August 14, 2007Assignee: CJ CorporationInventors: Young Hoon Park, Byoung Choon Lee, Jae Yong Park, Kwang Myung Cho, Yong Uk Shin
-
Patent number: 7247453Abstract: A Ca2+ dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin, in purification of Protein C, and in treatment of tumors.Type: GrantFiled: June 10, 1994Date of Patent: July 24, 2007Assignee: Oklahoma Medical Research FoundationInventors: Alireza Rezaie, Charles T. Esmon
-
Patent number: 7241614Abstract: The present invention relates to methods for producing a polypeptide of interest by (a) cultivating a mutant of a parent Aspergillus cell, wherein (i) the mutant comprises a first nucleic acid sequence encoding the polypeptide and a second nucleic acid sequence comprising a modification of at least one of the genes responsible for the biosynthesis or secretion of at least one toxin, and (ii) the mutant produces less of the toxin than the parent Aspergillus cell when cultured under the same conditions; and (b) isolating the polypeptide from the culture medium. Also, mutants of Aspergillus cells are provided, as well as methods for obtaining the mutant cells.Type: GrantFiled: October 26, 2004Date of Patent: July 10, 2007Assignee: Novozymes A/SInventors: Bjorn Eggert Christensen, Henrik Mollgaard, Svend Kaasgaard, Jan Lehmbeck
-
Patent number: 7241594Abstract: Nucleotide sequences encoding formate dehydrogenases D & E and a method for preparing succinic acid using the same, more particularly, formate dehydrogenases D & E converting formate to carbon dioxide and hydrogen, fdhD and fdhE nucleotide sequences encoding the formate dehydrogenases D & E, recombinant vectors containing the nucleotide sequences, microorganisms transformed with the recombinant vectors, and a method for preparing succinic acid using the transformed microorganism.Type: GrantFiled: September 16, 2005Date of Patent: July 10, 2007Assignee: Korea Advanced Institute of Science and TechnologyInventors: Sang Yup Lee, Hyohak Song, Yu Sin Jang, Sung Won Lim
-
Patent number: 7241590Abstract: The present invention describes a newly discovered full-length polynucleotide encoding an SH2 domain-containing adapter protein, called human MIST, cloned, isolated and identified from a human spleen cDNA library. Also described are the MIST polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Novel splice variant forms of human MIST are provided. Methods for screening for modulators, particularly inhibitors, of the MIST protein and use of the human MIST polynucleotide and polypeptide for therapeutics and diagnostics are described.Type: GrantFiled: September 28, 2001Date of Patent: July 10, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Juan J. Perez-Villar, Han Chang, Wen-Pin Yang, Yuli Wu, Gena S. Whitney, Steven B. Kanner
-
Patent number: 7229794Abstract: Provided are a microorganism capable of producing L-threonine and having an inactivated galR gene, a method of producing the same and a method of producing L-threonine using the microorganism. The microorganism can be used to produce L-threonine in high yield.Type: GrantFiled: February 4, 2005Date of Patent: June 12, 2007Assignee: CJ CorporationInventors: Young Hoon Park, Byoung Choon Lee, Kwang Myung Cho, Dae Cheol Kim, Yong Uk Shin, Jin Ho Lee
-
Patent number: 7227010Abstract: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A.Type: GrantFiled: November 6, 2001Date of Patent: June 5, 2007Assignee: United States of America as Represented by the Secretary of the ArmyInventor: Leonard A. Smith
-
Patent number: 7223567Abstract: The invention relates to a mutant strain of bacteria, which either lacks or contains mutant genes for several key metabolic enzymes, and which produces high amounts of succinic acid under anaerobic conditions.Type: GrantFiled: August 29, 2005Date of Patent: May 29, 2007Assignee: Rice UniversityInventors: San Ka-Yiu, George N. Bennett, Ailen Sanchez
-
Patent number: 7214787Abstract: This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as weel as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.Type: GrantFiled: July 6, 2000Date of Patent: May 8, 2007Assignee: United States of America as Represented by the Secretary of the ArmyInventors: Leonard A. Smith, Michael P. Byrne, John L. Middlebrook, Hugh Lapenotiere, Michael A. Clayton, Douglas R. Brown
-
Patent number: 7208292Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: March 9, 2006Date of Patent: April 24, 2007Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7202059Abstract: Fusion protein including a fusion part and a protein of interest, the combination of the two proteins leading to the fusion protein being secreted into a supernatant of a bacterial host with the protein of interest being present in its correct three-dimensional structure. Nucleic acid including a sequence coding for a fusion protein, the sequence including: —F—Asm—Rn—Y—, where F is a nucleic acid sequence coding for an amino acid sequence which allows secretion of a protein encoded by Y into a fermentation medium, As is a chemical bond or a nucleic acid sequence comprising a codon, m is an integer from 0–10, R is a chemical bond or an arginine codon, n is 0 or 1, and Y is a nucleic acid sequence coding for a protein of interest. Processes therefor.Type: GrantFiled: February 19, 2002Date of Patent: April 10, 2007Assignees: Sanofi-Aventis Deutschland GmbH, Wacker-Chemie GmbHInventors: Paul Habermann, Johann Ertl
-
Patent number: 7198918Abstract: A polypeptide which contains the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing encoded by a gene originating in human being. Because of serving as a chemical efficacious in the suppression of the proliferation and differentiation of undifferentiated blood cells, this polypeptide is expected to be usable in medicines and medical supplies.Type: GrantFiled: January 27, 2005Date of Patent: April 3, 2007Assignee: Asahi Kasei Kabushiki KaishaInventors: Seiji Sakano, Akira Itoh
-
Patent number: 7192742Abstract: (Beauveria) sp. FO-6979 (FERM BP-6681), which belongs to the genus Beauveria and is capable of producing FO-6979-M0, -M1, -M2, -M3 and -M4 substances, is cultured in a medium to thereby accumulate the FO-6979-M0, -M1, -M2, -M3 and -M4 substances in the liquid culture medium. Then the FO-6979-M0, -M1, -M2, -M3 and -M4 substances are collected from the culture medium. The substances thus obtained are less toxic, specifically inhibit acyl-Coenzyme A: cholesterol acyltransferase, and inhibit the formation of oil droplets in macrophages. Owing to these characteristics, the above substances are useful in preventing and treating human diseases caused by cholesterol accumulation.Type: GrantFiled: March 19, 2002Date of Patent: March 20, 2007Assignees: Gakkou Houjin Kitasato Gakeun, Japan Society for the Promotion of ScienceInventors: Satoshi Omura, Hiroshi Tomoda
-
Patent number: 7189550Abstract: The present invention provides a protein having ?1,3-galactosyltransferase activity, a DNA encoding the protein, a transformant comprising the DNA, a process for producing the protein using the transformant, and a process for producing a galactose-containing complex carbohydrate using the transformant.Type: GrantFiled: September 16, 2005Date of Patent: March 13, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuo Endo, Satoshi Koizumi
-
Patent number: 7179622Abstract: A polypeptide which contains the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing encoded by a gene originating in human being. Because of serving as a chemical efficacious in the suppression of the proliferation and differentiation of undifferentiated blood cells, this polypeptide is expected to be usable in medicines and medical supplies.Type: GrantFiled: January 27, 2005Date of Patent: February 20, 2007Assignee: Asahi Kasei Kabushiki KaishaInventors: Seiji Sakano, Akira Itoh
-
Patent number: 7169912Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: October 25, 2001Date of Patent: January 30, 2007Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
-
Patent number: 7157245Abstract: Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal Neisseria or an extract of a commensal Neisseria. Further methods and compositions comprise commensal Neisseria which express genes from virulent strains of Neisseria and/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.Type: GrantFiled: August 31, 2001Date of Patent: January 2, 2007Assignee: Health Protection AgencyInventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Philippa Bracegirdle, John Simon Kroll, Paul Richard Langford, Steven Anthony Rochford Webb, Keith Cartwright, Cliona Anne O'Dwyer, Karen Margaret Reddin
-
Patent number: 7125690Abstract: Isolated DNAs which are DNAs having a base sequence represented by any of SEQ ID NOS: 1 to 6 in Sequence Listing or fragments thereof and showing a stationary phase-specific promoter activity in Gram-positive bacteria.Type: GrantFiled: March 13, 2002Date of Patent: October 24, 2006Assignee: Takara Bio Inc.Inventors: Tomoko Shimojo, Hikaru Takakura, Kazuyori Ochiai, Kiyozo Asada, Ikunoshin Kato
-
Patent number: 7125679Abstract: A minicell display method has been developed which has significant advantages for screening peptide libraries for candidates that can bind and effectively modulate a particular biological process. The method, based on the small, anucleate minicell, has increased versatility in generating unique sequences to screen as well as increasing the size of the peptides to be screened. In vivo mutagenesis, at the level of protein synthesis, as well as DNA replication, increases diversification of the library to be screened and therefore substantially increases the number of potential peptides that can modulate a particular biological response or mechanism.Type: GrantFiled: March 6, 2002Date of Patent: October 24, 2006Assignee: Children's Medical Center CorporationInventor: Samy Ashkar
-
Patent number: 7122352Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: February 27, 2004Date of Patent: October 17, 2006Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman
-
Patent number: 7115725Abstract: Disclosed is DNA encoding diphtheria toxin polypeptides having multiple mutations, which render the polypeptides useful as vaccines.Type: GrantFiled: August 20, 2002Date of Patent: October 3, 2006Assignee: President and Fellows of Harvard CollegeInventor: R. John Collier
-
Patent number: 7105317Abstract: This invention relates to an immunogenic composition comprising a bacterial extract containing at least one expression products of the vrg genes of a strain of Bordetella chosen from B. pertussis, B. parapertussis, or B. bronchiseptica. The invention also relates to a method for producing the extract, comprising culturing the bacteria on blood medium to obtain isolated nonhemolytic colonies; inoculating cells of one or more colonies in liquid medium to give a suspension of cells; separating the cells from the liquid medium after culture; suspending the separated cells in a buffer comprising urea for at least an amount of time sufficient to form a bacterial lysate; and separating intact cells and insoluble material from soluble material, wherein the extract comprises the soluble material.Type: GrantFiled: March 10, 2003Date of Patent: September 12, 2006Assignee: Institut PasteurInventors: Pascale Gueirard, Nicole Guiso
-
Patent number: 7105653Abstract: The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.Type: GrantFiled: April 17, 2004Date of Patent: September 12, 2006Inventors: Armen B. Shanafelt, Jeffrey M. Greve, Gary Jesmok, Kenneth Lembach, Gayle D. Wetzel
-
Patent number: 7094579Abstract: The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences.Type: GrantFiled: February 13, 2002Date of Patent: August 22, 2006Assignee: XOMA Technology Ltd.Inventors: Jeff Gray, Joe Buechler, Uday Kumar Veeramallu
-
Patent number: 7078193Abstract: The present invention provides a polypeptide, called EspA, which is secreted by pathogenic E. coli, such as the enteropathogenic (EPEC) and enterohemorrhagic (EHEC) E. coli. The invention also provides isolated nucleic acid sequences encoding EspA polypeptide, EspA peptides, a recombinant method for producing recombinant EspA, antibodies which bind to EspA, and a kit for the detection of EspA-producing E. coli.Type: GrantFiled: September 28, 2001Date of Patent: July 18, 2006Assignee: University of British ColumbiaInventors: B. Brett Finlay, Brendan Kenny, Markus Stein, Michael S. Donnenberg, Li-Ching Lai
-
Patent number: 7078027Abstract: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.Type: GrantFiled: May 2, 2002Date of Patent: July 18, 2006Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Jian Ni, Craig A. Rosen
-
Patent number: 7074411Abstract: A recombinant heteromultimeric protein including at least (a) a polypeptide fusion molecule A consisting of a C4BP ?-chain C-terminal fragment and a polypeptide fragment heterologous to said ?-chain, and (a) a polypeptide fusion molecule B consisting of a C4BP ?-chain C-terminal fragment and a polypeptide fragment heterologous to said ?-chain, wherein (a) and (b) are linked in the C-terminal portion to form said multimeric protein.Type: GrantFiled: July 18, 1996Date of Patent: July 11, 2006Assignees: Universite Pierre et Marie Curie (Paris VI), Universite de Reims Champagne-ArdennesInventors: David Klatzmann, Jacques Cohen
-
Patent number: 7070944Abstract: Methods for identifying modulators of fatty acid transport and/or uptake, comprising contacting, under conditions favorable for fatty acid uptake, a putative modulator, e.g., an inhibitor with a system comprising genetic material encoding a fatty acid transport mediator (“TTM”), particularly FAA1, FAA2, FAA3, FAA4, FAT1, fadL, fadD, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, or fatty acid transport mediator proteins (“TTMps”), e.g., Faa1p, Faa2p, Faa3p, Faa4p, Fat1p, FadL, fatty acyl CoA synthetase, FATP, CD36 and FABP, or orthologs, homologs, isoforms, variants, analogs, derivatives or fragments thereof, and combinations thereof, and determining the effect of the putative modulator. The test system may be a cell such as Saccharomyces cerevisiae, E. coli, H. sapiens, etc. or an in vitro system.Type: GrantFiled: March 14, 2002Date of Patent: July 4, 2006Assignee: CLF Medical Technology Acceleration Program, Inc.Inventors: Paul Black, Concetta DiRusso
-
Patent number: 7063950Abstract: Isolated DNA encoding each of human calcium channel ?1-, ?2-, ?- and ?-subunits, including subunits that arise as splice variants of primary transcripts, is provided. Cells and vectors containing the DNA and methods for identifying compounds that modulate the activity of human calcium channels are also provided.Type: GrantFiled: March 13, 1995Date of Patent: June 20, 2006Inventors: Michael M. Harpold, Steven B. Ellis, Mark E. Williams
-
Patent number: 7060261Abstract: The present invention relates to a novel CK?-5 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-5 protein. CK?-5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK?-5 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: April 3, 2002Date of Patent: June 13, 2006Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Yi Li, Jian Ni, Craig A. Rosen, Steven M. Ruben
-
Patent number: 7060276Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: March 25, 2002Date of Patent: June 13, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
-
Patent number: 7056672Abstract: Compositions and methods for identifying nucleotide fragments that contain an open reading frame are provided. Compositions comprise a nucleotide sequence that encodes, in each of the three possible reading frames, an ATG start codon and a histidine tag, and vectors comprising such a nucleotide sequence. The vectors may be provided with cloning sites for insertion of nucleotide sequences of interest 5? or 3? to the 3-frame His-tag DNA sequence. Vectors also are provided with cloning sites for inserting nucleotide sequences of interest 3? of the ATG start codon and 5? of the 3-frame His-tag DNA sequence.Type: GrantFiled: January 27, 2004Date of Patent: June 6, 2006Assignee: Iowa State University Research Foundation, Inc.Inventors: Patrick S. Schnable, Feng Liu, Yan Fu
-
Patent number: 7045611Abstract: The invention relates to a nucleic acid molecule, comprising a nucleic acid which codes for a polypeptide with chorismate mutase activity and derivatives thereof, whereby the derivatives have at least 10% of the chorismate mutase activity of the chorismate mutase, according to the identification number of the SEQ ID NO:2. The invention further relates to vectors containing nucleic acid molecules, to host cells comprising nucleic acid molecules and their use in methods for producing polypetides with chorismate mutase activity. The invention also relates to the polypeptides with chorismate mutase activity and antibodies which specifically recognize the same. In addition, the invention relates to methods for producing auxotrophic yeast strains using the nucleic acid molecules and to the preparation of the yeast strains.Type: GrantFiled: October 25, 2001Date of Patent: May 16, 2006Assignee: Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbHInventors: Gerd Gellissen, Gerhard Braus, Ralph Pries, Sven Krappmann, Alexander W. Strasser
-
Patent number: 7041474Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: March 1, 2001Date of Patent: May 9, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventor: Gillian Kingsbury
-
Patent number: 7037680Abstract: Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT/A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT/A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT/A.Type: GrantFiled: November 6, 2001Date of Patent: May 2, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Leonard A. Smith, Melody Jensen
-
Patent number: 7033789Abstract: The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Schistocerca americana (grasshopper) glutamate-gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding S. americana glutamate-gated chloride channels, substantially purified forms of associated S. americana glutamate-gated chloride channels and recombinant membrane fractions comprising these proteins, associated mutant proteins, and methods associated with identifying compounds which modulate associated Schistocerca americana glutamate-gated chloride channels, which will be useful as insecticides.Type: GrantFiled: October 19, 2000Date of Patent: April 25, 2006Assignee: Merck & Co., Inc.Inventors: Michel J. Hamelin, Jeffrey W. Warmke
-
Patent number: 7033772Abstract: A family of fatty acid transport proteins (FATPs) mediate transport of long chain fatty acids (LCFAs) across cell membranes into cells. These proteins exhibit different expression patterns among the organs of mammals. Nucleic acids encoding FATPs of this family, vectors comprising these nucleic acids, as well as the production of FATP proteins in host cells are described. Also described are methods to test FATPs for fatty acid transport function, and methods to identify inhibitors or enhancers of transport function. The altering of LCFA uptake by administering to the mammal an inhibitor or enhancer of FATP transport function of a FATP in the small intestine can decrease or increase calories available as fats, and can decrease or increase circulating fatty acids. The organ specificity of FATP distribution can be exploited in methods to direct drugs, diagnostic indicators and so forth to an organ such as the heart.Type: GrantFiled: September 23, 1999Date of Patent: April 25, 2006Assignees: Millennium Pharmaceuticals, Inc., Whitehead Institute for Biomedical ResearchInventors: Andreas Stahl, David J. Hirsch, Harvey F. Lodish, Ruth E. Gimeno, Louis A. Tartaglia
-
Patent number: 7001595Abstract: The present invention relates to deletion and substitution mutant polypeptides of human chemokine ?-7 (Ck?-7), as well as nucleic acid molecules encoding such polypeptides and processes for producing such polypeptides using recombinant techniques. In one aspect, the invention also relates to uses of the full-length and mature forms of Ck?-7, as well as deletion and substitution mutants, in medical treatment regimens. In particular, the Ck?-7 polypeptides described herein may be employed to treat a variety of conditions, including rheumatoid arthritis, inflammation, respiratory diseases, allergy, and IgE-mediated allergic reactions.Type: GrantFiled: October 1, 2002Date of Patent: February 21, 2006Assignees: Human Genome Sciences Inc., Beatson Institute for Cancer ResearchInventors: Theodora W. Salcedo, Vikram P. Patel, Robert John Benjamin Nibbs, Gerard John Graham
-
Patent number: 6998476Abstract: Disclosure herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.Type: GrantFiled: June 6, 2002Date of Patent: February 14, 2006Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Wlodzimierz Maslinski
-
Patent number: RE39015Abstract: Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using the reagents and diagnostic kits are also provided.Type: GrantFiled: August 22, 2001Date of Patent: March 14, 2006Assignee: Schering CorporationInventor: J. Fernando Bazan